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Background and Purpose: In order to use a single implant with one treatment plan in fractionated high-dose-rate brachy-
therapy (HDR-B), applicator position shifts must be corrected prior to each fraction. The authors investigated the use of gold 
markers for X-ray-based setup and position control between the single fractions.
Patients and Methods: Caudad-cephalad movement of the applicators prior to each HDR-B fraction was determined on radio-
graphs using two to three gold markers, which had been inserted into the prostate as intraprostatic reference, and one to two 
radiopaque-labeled reference applicators. 35 prostate cancer patients, treated by HDR-B as a monotherapy between 10/2003 and 
06/2006 with four fractions of 9.5 Gy each, were analyzed. Toxicity was scored according to the CTCAE Score, version 3.0. Median 
follow-up was 3 years.
Results: The mean change of applicators positions compared to baseline varied substantially between HDR-B fractions, being 
1.4 mm before fraction 1 (range, –4 to 2 mm), –13.1 mm before fraction 2 (range, –36 to 0 mm), –4.1 mm before fraction 3 (range, 
–21 to 9 mm), and –2.6 mm at fraction 4 (range, –16 to 9 mm). The original position of the applicators could be readjusted easily 
prior to each fraction in every patient. In 18 patients (51%), the applicators were at least once readjusted > 10 mm, however, 
acute or late grade ≥ 2 genitourinary toxicity was not increased (p = 1.0) in these patients.
Conclusion: Caudad position shifts up to 36 mm were observed. Gold markers represent a valuable tool to ensure setup accuracy 
and precise dose delivery in fractionated HDR-B monotherapy of prostate cancer.
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Nutzen von Goldmarkern zur Konfiguration bei der bildgestützten, fraktionierten High-Dose-Rate-Brachytherapie als 
Monotherapie des Prostatakarzinoms
Hintergrund und Ziel: Um ein einziges Implantat mit einem Bestrahlungsplan für die fraktionierte High-Dose-Rate-Brachythe-
rapie (HDR-B) nutzen zu können, müssen Positionsverschiebungen der Katheter vor jeder Fraktion erkannt und korrigiert werden. 
Die Autoren untersuchten den Nutzen von Goldmarkern für röntgenbildbasierte Konfiguration und Positionskontrolle zwischen 
den Einzelfraktionen.
Patienten und Methodik: Die kraniokaudalen Verschiebungen der Applikatoren wurden vor jeder HDR-B-Fraktion anhand von 
zwei bis drei Goldmarkern als intraprostatische Referenz und ein bis zwei röntgendicht markierten Referenzapplikatoren mittels 
Röntgenbild bestimmt. 35 Patienten mit Prostatakarzinom, welche zwischen 10/2003 and 06/2006 eine HDR-B als Monotherapie 
mit vier Fraktionen von jeweils 9,5 Gy erhielten, wurden untersucht. Die Behandlungstoxizität wurde mit dem CTCAE-Score, Ver-
sion 3.0, erfasst. Die mediane Nachbeobachtungszeit lag bei 3 Jahren.
Ergebnisse: Die mittlere Positionsabweichung der Applikatoren von der Sollposition variierte erheblich zwischen den HDR-B-Frak-
tionen und betrug 1,4 mm vor der ersten Fraktion (Spannweite: –4 bis 2 mm), –13,1 mm vor der zweiten Fraktion (Spannweite: 
–36 bis 0 mm), –4,1 mm vor der dritten Fraktion (Spannweite: –21 bis 9 mm) und –2,6 mm vor der vierten Fraktion (Spannweite: 
–16 bis 9 mm). Die ursprüngliche Position der Applikatoren konnte bei jedem Patienten problemlos vor jeder Fraktion wieder-
hergestellt werden. Bei 18 Patienten (51%) wurden die Applikatoren wenigstens einmal > 10 mm verschoben; dennoch war die 
genitourethrale Akut- oder Spättoxizität Grad ≥ 2 bei diesen Patienten nicht erhöht (p = 1,0).
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Introduction
Prostate cancer (PCA) as the most commonly diagnosed can-
cer among men in Europe and North America [2, 15] after skin 
cancer has various treatment possibilities. For patients with 
low- and intermediate-risk PCA active surveillance, radical 
prostatectomy, external-beam radiation therapy (EBRT), 
low-dose-rate brachytherapy (LDR-B) and high-dose-rate 
brachytherapy (HDR-B) are arguable treatment options. 
Several reports on HDR-B in combination with EBRT have 
been published [1, 5, 7, 9, 13, 17, 19, 21], but HDR-B as a 
monotherapy is a relatively new approach. Different frac-
tionation schedules are described in the literature with the 
single dose ranging from 6 to 10.5 Gy and the number of 
fractions ranging from three to nine with a minimum interval 
of 6 h between the subsequent fractions. Generally, for lo-
gistic and economic reasons one implant and one treatment 
plan are used [4, 10, 11, 16, 18, 25–27]. However, there are 
no standard criteria or guidelines for repeating imaging and 
dosimetry for each fraction after a single implant. Martinez 
et al. were the first to introduce a fractionation scheme with 
four single fractions of 9.5 Gy each [18], which was adopted 
by us and others [10, 16]. In their pioneering report, they 
described the caudad-cephalad movement of the applicators 
prior to each fraction in a subgroup of their patients. The 
mean applicator movement peaked before the second frac-
tion being 20 mm (range, 10–31 mm) in the caudad direction 
which was measured by fluoroscopy after filling the bladder 
with contrast material. Given the typical HDR-B treatment 
length of 35–50 mm, it is obvious that applicator dislocations 
of > 10 mm may have a devastating impact on the accurate 
treatment delivery of subsequent fractions if only one im-
plant and one treatment plan are used. It is therefore funda-
mental to detect and correct these dislocations prior to each 
fraction.
In this study, we have investigated the use of gold mark-
ers for a simple X-ray-based setup and position control be-
tween the single fractions in HDR-B monotherapy for PCA. 
Feasibility of this approach, direction and magnitude of the 
dislocations between the fractions, as well as their associa-
tions with the acute and late genitourinary (GU) toxicity are 
reported.
Patients and Methods
Patient Selection, Characteristics, and Implant
A total of 36 patients with histologically proven adenocar-
cinoma of the prostate were treated by HDR-B as a mono-
therapy between 10/2003 and 06/2006, as previously described 
[10]. Briefly, these patients were staged according to the 2002 
American Joint Committee on Cancer tumor, lymph nodes 
and metastasis system [24].
All patients received one implant and four separate frac-
tions of HDR-B delivered within 48 h. Fraction dose was 9.5 
Gy, the total prescribed dose was 38 Gy. The minimal inter-
val between fractions was 6 h. For the implantation of the 
applicators, patients underwent spinal anesthesia and were 
placed in lithotomy position. The applicators were implanted 
by an urologist by transperineal placement under real-time 
transrectal ultrasound (TRUS) guidance using a template for 
parallel needle insertion. Patients received a variable number 
of needles depending on the prostate size and configuration. 
Axial cross sections were acquired in 5-mm steps and trans-
ferred to the Plato® treatment-planning software (Nucletron, 
Veenendaal, The Netherlands). Dose optimization was done 
on the reconstructed applicator geometry using dose point 
and manual optimization algorithms.
After implantation of the applicators, patients received 
two to three gold markers (diameter: 0.9 mm, length: 7 mm), 
implanted under TRUS guidance. One to two applicators 
served as reference being visualized on the X-ray by insertion 
of a radiopaque dummy wire. A reference X-ray was taken 
in anterior-posterior direction right after the correct position 
of the catheters had been confirmed by ultrasound at the end 
of the implantation. Applicators were then sutured to the 
perineum. X-rays were taken before the first, second, third, 
and fourth fraction. In case of dislocation > 2 mm all applica-
tors were replaced until complete agreement was found with 
the reference X-ray. X-rays were analyzed retrospectively 
and the incidence and the magnitude of applicator disloca-
tions were recorded. One patient was excluded because the 
radiographs were not available; thus, the study population 
consisted of 35 patients. Patients were grouped according to 
their risk of recurrence according to the National Comprehen-
sive Cancer Network practice guidelines in oncology (http://
www.nccn.org). 27 patients were classified as low risk (77%) 
and eight patients as high risk (23%). Patients’ median age 
was 64 years (range, 46–81 years). The median follow-up was 
3 years (range, 0.4–4.0 years). Patients received a mean num-
ber of 13.6 applicators (range, 10–18 applicators) represent-
ing a total of 475 applicators. For irradiation, a high-dose-rate 
afterloading system (Nucletron) with a 192Ir stepping source 
was used. This study was approved by the institutional ethics 
committee.
Schlussfolgerung: Positionsverschiebungen von bis zu 36 mm nach kaudal wurden beobachtet. Goldmarker sind bei der frak-
tionierten HDR-B-Monotherapie des Prostatakarzinoms von Nutzen, um die akkurate Konfiguration und die präzise Verabreichung 
der Strahlendosis zu gewährleisten.
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Follow-Up Protocol, Toxicity Scoring, and Biochemical 
Failure
Patients were seen by a radiation oncologist twice daily during 
the radiation monotherapy. Follow-up visits were arranged 
2–4 weeks after completion of HDR-B, every 3–6 months for 
the first 2 years, and annually thereafter with a digital-rectal 
examination and a serum prostate-specific antigen (PSA) lev-
el obtained at each visit. Patients alternated follow-up visits 
between their urologist and radiation oncologist. None of the 
patients were lost to follow-up.
The symptoms dysuria, incontinence, retention, frequen-
cy/urgency, and hematuria were graded using the common 
terminology criteria for adverse events from the National 
Cancer Institute (CTCAE version 3.0; http://ctep.cancer.gov/
forms/CTCAEv3.pdf). Late toxicity was defined as complica-
tions occurring within 3 months after the end of treatment.
Biochemical no evidence of disease (bNED) was assessed 
according to the Phoenix criteria, defining a biochemical fail-
ure as a PSA rise of ≥ 2 ng/ml above the nadir PSA [23].
Statistical Analysis
The primary endpoint was the occurrence of interfractional 
applicator dislocation > 10 mm and the secondary endpoint 
was the occurrence of acute or late grade ≥ 2 GU toxicity. 
Acute and late (grade 0–1 vs. grade 2–3) GU toxicities were 
grouped and compared with occurrence of interfractional ap-
plicator dislocation > 10 mm using Fisher’s exact test. Inter-
fractional applicator dislocation > 10 mm was compared with 
the size of the planning target volume (PTV) and the number 
of needles using the Mann-Whitney U-test. Statistical sig-
nificance was considered on a two-sided significance level (α)
 of = 0.05. Statistical analysis was performed with SPSS version 
16.0 (SPSS Inc., Chicago, IL, USA).
Results
Direction and Magnitude of Applicator Dislocations
17 patients (49%) had received two and 18 patients (51%) 
had received three gold markers as intraprostatic reference. 
In nine patients (26%), one radiopaque-labeled reference ap-
plicator and in 26 patients (74%), two reference applicators 
were used.
Dislocations of the applicators > 2 mm were observed 
at least once in 32 out of 35 patients (91%), with the total 
number of dislocations > 2 mm being 69, 63 of which where 
dislocations in the caudal direction (91%). Interestingly, the 
six observed dislocations in the cepha-
lad direction occurred only before the 
third (n = 3) and the fourth (n = 3) frac-
tion. Mean and median dislocations and 
ranges between the fractions are sum-
marized in Table 1. Before the first frac-
tion, correction of the catheter position 
was performed in one patient. Before 
the second, third, and fourth fraction, 
corrections were performed in 30, 19, 
and 19 patients, respectively (Figure 1). 
Dislocations of the applicators > 10 mm 
were at least once observed in 18 out 
of 35 patients (51%). Corrections > 10 
mm were not necessary before the first 
fraction but were performed in 18, four, 
and two patients before the second, 
third, and fourth fraction, respectively. 
Dislocations of the applicators > 20 mm 
were at least once observed in seven out 
of 35 patients (20%). Corrections > 20 
mm were performed in six and one pa-
tient before the second and third frac-
tion, respectively. However, the origi-
nal position of the applicators could be 
Table 1. Observed interfractional applicator shifts. –: shift in the caudal 
direction; +: shift in the cephalad direction.
Tabelle 1. Beobachtete Applikatorverschiebungen zwischen den Frak-
tionen. –: Verschiebung in die kaudale Richtung; +: Verschiebung in die 
kraniale Richtung. 
 Mean and median applicator dislocations
 range (mm)
Before fraction 1   +1.4 and 0 (–4 to +2)
Before fraction 2 –13.1 and –11 (–36 to 0)
Before fraction 3   –4.1 and –2 (–21 to +9)
Before fraction 4   –2.6 and –2 (–16 to +9)
Figures 1a and 1b. The reference X-ray showing the position of two reference catheters relative 
to the two implanted gold markers (a). Before the second fraction, both catheters are dislocated 
caudally, with a maximal magnitude of 10 mm (b).
Abbildungen 1a und 1b. Das Referenzröntgenbild zeigt die Position der beiden Referenzkatheter 
relativ zu den zwei implantierten Goldmarkern (a). Vor der zweiten Fraktion sind beide Katheter 
nach kaudal disloziert, mit einer maximalen Verschiebung von 10 mm (b).
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readjusted easily prior to each fraction in every patient and 
HDR-B was carried out as scheduled. After readjustment of 
the applicators, there were no position shifts in left-right direc-
tion observed. A new treatment plan was not required in any 
patient.
Correction of Applicator Dislocation and Treatment Toxicity
After treatment, acute grade 1, 2, or 3 GU toxicity occurred in 
15 (43%), 14 (40%), and one (3%) patients, respectively. Late 
grade 1, 2, and 3 GU toxicity occurred in twelve (34%), eight 
(23%), and four (11%) patients, respectively.
Occurrence of applicator dislocation > 10 mm and their 
subsequent correction were not associated with increased 
acute or late grade ≥ 2 GU toxicity (both, p = 1.0).
Further, occurrence of applicator dislocation > 10 mm 
was not associated with the PTV size (p = 0.86) nor with the 
number of needles used (p = 0.98).
Overall survival and biochemical control of patients after 
3 years was 100%; thus, no association with the occurrence of 
applicator dislocations could be determined.
Discussion
If radiotherapy is chosen for treatment of PCA, dose-escalated 
intensity-modulated radiation therapy is often considered the 
gold standard treatment for all risk groups [12, 22]. However, 
due to the very low α/β ratio of 1.5 Gy of PCA [3, 6, 8] which 
makes the cancer cells sensitive to hypofractionation, HDR-B 
may play a more dominant role in the treatment of PCA in the 
future. While HDR-B is widely used as a boost to EBRT, the 
use of HDR-B as a monotherapy for PCA remains experimen-
tal. The 4 × 9.5 Gy schedule for HDR-B as a monotherapy of 
low-risk patients was introduced by Martinez et al. [18]. Before 
each fraction, the bladder was filled with contrast material and 
fluoroscopy was performed to record the relationship of the tip 
of the needles to the bony anatomy and the bladder base. Any 
applicator movement in the caudad-cephalad direction was 
noted and corrected under fluoroscopy. For ten patients the 
mean interfractional movement was described which peaked 
before the second fraction being 20 mm (range, 10–31 mm) 
in the caudad direction. Moreover, Martinez et al. showed an 
increase of the prostate volume of approximately 20% after 
insertion of the needles, probably related to prostatic bleed-
ing and/or edema. However, during the subsequent 32–36 h 
the prostate volume did not differ substantially. The 4 × 9.5 
Gy fractionation scheme has also been used by Martin et al. 
[16]. In their report, they stated that needle movement in the 
caudad-cephalad direction was controlled, however, details 
concerning the technique which was therefore used are lack-
ing. The effectiveness of HDR-B monotherapy in intermedi-
ate- and even high-risk PCA has been shown by Yoshioka et 
al., using higher doses with a total dose up to 54 Gy delivered 
in eight to nine fractions of 6 Gy with the patients restricted to 
bed for 5 days [25–27]. However, details concerning the control 
of interfractional applicator motion are lacking. One phase II 
dose-escalation study by Hoskin et al. has compared HDR-B 
monotherapy with 34 Gy in four fractions, 36 Gy in four frac-
tions, and 31.5 Gy in three fractions [14]. Computed tomog-
raphy was performed before the second and fourth fraction 
and catheters were readjusted if they were dislocated > 5 mm 
[14]. We have used the 4 × 9.5 Gy fractionation scheme with 
ultrasound-based postplanning. Gold markers and radiopaque-
labeled reference applicators were used for X-ray-based setup 
and position control between the single fractions. Toxicity 
rates have been previously described [10], being comparable to 
the two existing studies using the same fractionation schedule 
[16, 18]. We observed substantial interfractional applicator dis-
locations, predominantly in the caudad direction, peaking be-
fore the second fraction, with the mean value being –13.1 mm 
(range, –36 to 0 mm). This can be explained by the postimplant 
prostate bleeding and/or edema with enlargement of the pros-
tate as it has been described by others [18]. Prostate edema, 
subsequent prostate volume changes, and changes of dosimet-
ric parameters after LDR-B were extensively described [20]. 
In our study, dislocations of the applicators ≤ 2 mm were toler-
ated, dislocations > 2 mm were corrected. This is a relatively 
low action level. Thus, applicators had to be readjusted in 91% 
of the patients. Since readjustment of the applicators requires 
intraprostatic manipulation which could potentially be associ-
ated with a trauma to the prostate, urethra or bladder, we were 
interested if readjustments > 10 mm were associated with in-
creased GU toxicity. However, we found no association with 
acute or late GU toxicity. Moreover, there was no association 
with the PTV size or the number of needles used. One limita-
tion of our study is the relatively short median follow-up with 
no patient experiencing biochemical relapse. If the follow-up 
matures, it will be interesting to compare the biochemical out-
come data with incidence and magnitude of applicator disloca-
tions to exclude insufficient PTV dose covering.
The consistency of the implant geometry between HDR-B 
fractions is of utmost importance for an appropriate dose de-
livery. Novel approaches such as real-time online planning 
have facilitated repetitive planning procedures, but are still 
laborious and time-consuming. We consider the use of gold 
markers for X-ray-based setup and position control between 
the single fractions a feasible and valuable tool for fraction-
ated HDR-B of the prostate.
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